Head-To-Head Comparison: Mednax (MD) vs. Its Competitors
Mednax (NYSE: MD) is one of 50 public companies in the “Healthcare Facilities & Services” industry, but how does it compare to its peers? We will compare Mednax to related businesses based on the strength of its valuation, analyst recommendations, risk, institutional ownership, dividends, profitability and earnings.
This table compares Mednax and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Mednax and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Mednax||$3.34 billion||$628.40 million||14.09|
|Mednax Competitors||$5.43 billion||$855.44 million||37.30|
Mednax’s peers have higher revenue and earnings than Mednax. Mednax is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
69.7% of shares of all “Healthcare Facilities & Services” companies are held by institutional investors. 2.4% of Mednax shares are held by insiders. Comparatively, 15.4% of shares of all “Healthcare Facilities & Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Mednax has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Mednax’s peers have a beta of 1.01, meaning that their average share price is 1% more volatile than the S&P 500.
This is a breakdown of current ratings for Mednax and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mednax currently has a consensus price target of $55.44, indicating a potential upside of 24.57%. As a group, “Healthcare Facilities & Services” companies have a potential downside of 5.37%. Given Mednax’s higher possible upside, equities research analysts plainly believe Mednax is more favorable than its peers.
Mednax peers beat Mednax on 9 of the 13 factors compared.
MEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.